{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:12:36Z","timestamp":1778620356034,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2314-B-006-031"],"award-info":[{"award-number":["MOST 110-2314-B-006-031"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 106-2314-B-006-064-MY2"],"award-info":[{"award-number":["MOST 106-2314-B-006-064-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 108-2314-B-006-043-MY2"],"award-info":[{"award-number":["MOST 108-2314-B-006-043-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007750","name":"National Cheng Kung University","doi-asserted-by":"publisher","award":["NCKUMCS2022075"],"award-info":[{"award-number":["NCKUMCS2022075"]}],"id":[{"id":"10.13039\/501100007750","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taiwan Osteoporosis Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00198-023-06845-0","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T07:05:49Z","timestamp":1689750349000},"page":"1783-1791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients"],"prefix":"10.1007","volume":"34","author":[{"given":"Yi-Lun","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-An","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Fan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawl-Shan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6735-4861","authenticated-orcid":false,"given":"Ta-Wei","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"6845_CR1","doi-asserted-by":"crossref","unstructured":"Lyles KW et al. (2007) Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. New England J Med 357(18)","DOI":"10.1056\/NEJMoa074941"},{"issue":"6","key":"6845_CR2","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.berh.2005.06.003","volume":"19","author":"TW O'Neill","year":"2005","unstructured":"O\u2019Neill TW, Roy DK (2005) How many people develop fractures with what outcome? Best Pract Res Clin Rheumatol 19(6):879\u2013895","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"10","key":"6845_CR3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrendo.2014.125","volume":"10","author":"SE Sattui","year":"2014","unstructured":"Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10(10):592\u2013602","journal-title":"Nat Rev Endocrinol"},{"key":"6845_CR4","doi-asserted-by":"crossref","unstructured":"Tai TW et al. (2022) The Impact of Various Anti\u2010Osteoporosis Drugs on All\u2010Cause Mortality After Hip Fractures: A Nationwide Population Study. J Bone Mineral Res","DOI":"10.1002\/jbmr.4627"},{"issue":"1","key":"6845_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13018-019-1226-6","volume":"14","author":"O Guzon-Illescas","year":"2019","unstructured":"Guzon-Illescas O et al (2019) Mortality after osteoporotic hip fracture: incidence, trends, and associated factors. J Orthop Surg Res 14(1):1\u20139","journal-title":"J Orthop Surg Res"},{"issue":"6","key":"6845_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.6061\/clinics\/2012(06)02","volume":"67","author":"FJ Tarazona-Santabalbina","year":"2012","unstructured":"Tarazona-Santabalbina FJ et al (2012) Early interdisciplinary hospital intervention for elderly patients with hip fractures\u2013functional outcome and mortality. Clinics 67(6):547\u2013555","journal-title":"Clinics"},{"issue":"1","key":"6845_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12877-019-1278-9","volume":"19","author":"SF Yu","year":"2019","unstructured":"Yu SF et al (2019) Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score-matched cohort study. BMC Geriatr 19(1):290","journal-title":"BMC Geriatr"},{"key":"6845_CR8","doi-asserted-by":"publisher","first-page":"116216","DOI":"10.1016\/j.bone.2021.116216","volume":"154","author":"TW Tai","year":"2022","unstructured":"Tai TW et al (2022) Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: A nationwide population study. Bone 154:116216","journal-title":"Bone"},{"issue":"25","key":"6845_CR9","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","volume":"379","author":"IR Reid","year":"2018","unstructured":"Reid IR et al (2018) Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med 379(25):2407\u20132416","journal-title":"N Engl J Med"},{"issue":"9","key":"6845_CR10","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s00198-020-05378-0","volume":"31","author":"D Cornelissen","year":"2020","unstructured":"Cornelissen D et al (2020) Interventions to improve adherence to anti-osteoporosis medications: an updated systematic review. Osteoporos Int 31(9):1645\u20131669","journal-title":"Osteoporos Int"},{"issue":"1","key":"6845_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL et al (2022) Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther 39(1):58\u201374","journal-title":"Adv Ther"},{"issue":"10","key":"6845_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/1060028018768808","volume":"52","author":"P Morizio","year":"2018","unstructured":"Morizio P, Burkhart JI, Ozawa S (2018) Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients. Ann Pharmacother 52(10):1031\u20131041","journal-title":"Ann Pharmacother"},{"key":"6845_CR13","doi-asserted-by":"crossref","unstructured":"Rupp T et al. (2022) Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study. Osteoporosis Int 1\u20138","DOI":"10.1016\/j.bonr.2022.101267"},{"issue":"1","key":"6845_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/jcm10010152","volume":"10","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD et al (2021) Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review. J Clin Med 10(1):152","journal-title":"J Clin Med"},{"key":"6845_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"},{"issue":"1","key":"6845_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2021","unstructured":"Tsourdi E et al (2021) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 106(1):264\u2013281","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"6845_CR17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7326\/M20-0882","volume":"173","author":"H Lyu","year":"2020","unstructured":"Lyu H et al (2020) Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study. Ann Intern Med 173(7):516\u2013526","journal-title":"Ann Intern Med"},{"key":"6845_CR18","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.2147\/PPA.S316144","volume":"15","author":"C-F Huang","year":"2021","unstructured":"Huang C-F, Shiao M-S, Mao T-Y (2021) Retrospective Analysis of the Effects of Non-Compliance with Denosumab on Changes in Bone Mineral Density During the COVID-19 Pandemic. Patient Prefer Adherence 15:1579","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"6845_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-021-06085-0","volume":"33","author":"M Chandran","year":"2022","unstructured":"Chandran M et al (2022) Adherence to dosing schedule of denosumab therapy for osteoporosis during COVID-19 lockdown: an electronic medical record and pharmacy claims database study from Asia. Osteoporos Int 33(1):251\u2013261","journal-title":"Osteoporos Int"},{"key":"6845_CR20","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.2147\/DDDT.S270829","volume":"14","author":"K-L Pang","year":"2020","unstructured":"Pang K-L, Low NY, Chin K-Y (2020) A review on the role of denosumab in fracture prevention. Drug Des Dev Ther 14:4029","journal-title":"Drug Des Dev Ther"},{"issue":"6","key":"6845_CR21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1210\/jc.2010-2784","volume":"96","author":"S Boonen","year":"2011","unstructured":"Boonen S et al (2011) Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 96(6):1727\u20131736","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"6845_CR22","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1007\/s10067-021-05757-w","volume":"40","author":"YE Miedany","year":"2021","unstructured":"Miedany YE et al (2021) Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia? Clin Rheumatol 40(10):4225\u20134232","journal-title":"Clin Rheumatol"},{"issue":"12","key":"6845_CR23","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1111\/jgs.16165","volume":"67","author":"S Phu","year":"2019","unstructured":"Phu S et al (2019) Effect of denosumab on falls, muscle strength, and function in community-dwelling older adults. J Am Geriatr Soc 67(12):2660\u20132661","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"6845_CR24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.injury.2018.01.003","volume":"49","author":"R Men\u00e9ndez-Colino","year":"2018","unstructured":"Men\u00e9ndez-Colino R et al (2018) Baseline and pre-operative 1-year mortality risk factors in a cohort of 509 hip fracture patients consecutively admitted to a co-managed orthogeriatric unit (FONDA Cohort). Injury 49(3):656\u2013661","journal-title":"Injury"},{"issue":"7","key":"6845_CR25","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3390\/jcm8070932","volume":"8","author":"T-W Hsu","year":"2019","unstructured":"Hsu T-W et al (2019) Comparison of the effects of denosumab and alendronate on cardiovascular and renal outcomes in osteoporotic patients. J Clin Med 8(7):932","journal-title":"J Clin Med"},{"issue":"2","key":"6845_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2353\/ajpath.2009.080957","volume":"175","author":"S Helas","year":"2009","unstructured":"Helas S et al (2009) Inhibition of receptor activator of NF-\u03baB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 175(2):473\u2013478","journal-title":"Am J Pathol"},{"issue":"18","key":"6845_CR27","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1093\/hmg\/ddz124","volume":"28","author":"D Hamoudi","year":"2019","unstructured":"Hamoudi D et al (2019) An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic mice. Hum Mol Genet 28(18):3101\u20133112","journal-title":"Hum Mol Genet"},{"issue":"1","key":"6845_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/cvr\/cvs078","volume":"94","author":"S Ock","year":"2012","unstructured":"Ock S et al (2012) Receptor activator of nuclear factor-\u03baB ligand is a novel inducer of myocardial inflammation. Cardiovasc Res 94(1):105\u2013114","journal-title":"Cardiovasc Res"},{"key":"6845_CR29","doi-asserted-by":"crossref","unstructured":"Dhabhar B (2022) Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer. Breast Cancer 163\u2013173","DOI":"10.2147\/BCTT.S353332"},{"issue":"8","key":"6845_CR30","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3390\/cells10081978","volume":"10","author":"S Casimiro","year":"2021","unstructured":"Casimiro S et al (2021) The roadmap of RANKL\/RANK pathway in cancer. Cells 10(8):1978","journal-title":"Cells"},{"key":"6845_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.critrevonc.2018.10.011","volume":"133","author":"PA Van Dam","year":"2019","unstructured":"Van Dam PA et al (2019) RANK\/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol 133:85\u201391","journal-title":"Crit Rev Oncol Hematol"},{"key":"6845_CR32","doi-asserted-by":"crossref","unstructured":"Gnant M et al. (2018) Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. Am Soc Clin Oncol","DOI":"10.1200\/JCO.2018.36.15_suppl.500"},{"issue":"11","key":"6845_CR33","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1001\/jamainternmed.2019.2779","volume":"179","author":"SR Cummings","year":"2019","unstructured":"Cummings SR et al (2019) Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern Med 179(11):1491\u20131500","journal-title":"JAMA Intern Med"},{"issue":"2","key":"6845_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/jbmr.2043","volume":"29","author":"EJ Samelson","year":"2014","unstructured":"Samelson EJ et al (2014) RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk. J Bone Miner Res 29(2):450\u2013457","journal-title":"J Bone Miner Res"},{"issue":"4","key":"6845_CR35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00198-007-0466-1","volume":"19","author":"F Penning-van Beest","year":"2008","unstructured":"Penning-van Beest F et al (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19(4):511\u2013517","journal-title":"Osteoporos Int"},{"issue":"2","key":"6845_CR36","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00198-012-1984-z","volume":"24","author":"Y-K Soong","year":"2013","unstructured":"Soong Y-K et al (2013) Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int 24(2):511\u2013521","journal-title":"Osteoporos Int"},{"issue":"1","key":"6845_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-019-1278-9","volume":"19","author":"S-F Yu","year":"2019","unstructured":"Yu S-F et al (2019) Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score-matched cohort study. BMC Geriatr 19(1):1\u201311","journal-title":"BMC Geriatr"},{"issue":"1","key":"6845_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/ejhpharm-2017-001258","volume":"26","author":"MJF Lozano","year":"2019","unstructured":"Lozano MJF, S\u00e1nchez-Fidalgo S (2019) Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates. Eur J Hosp Pharm 26(1):4\u20139","journal-title":"Eur J Hosp Pharm"},{"issue":"9","key":"6845_CR39","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"JA Cramer","year":"2005","unstructured":"Cramer JA et al (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453\u20131460","journal-title":"Curr Med Res Opin"},{"key":"6845_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update. Endocr Pract 26:1\u201346","journal-title":"Endocr Pract"},{"key":"6845_CR41","unstructured":"Tu KN et al (2018) Osteoporosis: a review of treatment options.\u00a0P T 43(2):92"},{"issue":"4","key":"6845_CR42","first-page":"324","volume":"60","author":"JP Brown","year":"2014","unstructured":"Brown JP et al (2014) Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician 60(4):324\u2013333","journal-title":"Can Fam Physician"},{"issue":"6","key":"6845_CR43","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00198-015-3084-3","volume":"26","author":"C Klop","year":"2015","unstructured":"Klop C et al (2015) Long-term persistence with anti-osteoporosis drugs after fracture. Osteoporos Int 26(6):1831\u20131840","journal-title":"Osteoporos Int"},{"key":"6845_CR44","doi-asserted-by":"crossref","unstructured":"Siris ES et al. (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. in Mayo Clinic Proceedings. Elsevier","DOI":"10.4065\/81.8.1013"},{"issue":"20","key":"6845_CR45","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","volume":"165","author":"DH Solomon","year":"2005","unstructured":"Solomon DH et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165(20):2414\u20132419","journal-title":"Arch Intern Med"},{"issue":"5","key":"6845_CR46","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1210\/clinem\/dgz321","volume":"105","author":"H Lyu","year":"2020","unstructured":"Lyu H et al (2020) Delayed denosumab injections and bone mineral density response: an electronic health record-based study. J Clin Endocrinol Metab 105(5):1435\u20131444","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"6845_CR47","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00198-018-4759-3","volume":"29","author":"C Yeam","year":"2018","unstructured":"Yeam C et al (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporos Int 29(12):2623\u20132637","journal-title":"Osteoporos Int"},{"issue":"5","key":"6845_CR48","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/jpm11050341","volume":"11","author":"R Dobre","year":"2021","unstructured":"Dobre R et al (2021) Adherence to Anti-Osteoporotic Treatment and Clinical Implications after Hip Fracture: A Systematic Review. J Personalized Med 11(5):341","journal-title":"J Personalized Med"},{"issue":"6","key":"6845_CR49","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00198-017-3976-5","volume":"28","author":"C Roux","year":"2017","unstructured":"Roux C, Briot K (2017) Imminent fracture risk. Osteoporos Int 28(6):1765\u20131769","journal-title":"Osteoporos Int"},{"issue":"3","key":"6845_CR50","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s00198-005-2026-x","volume":"17","author":"S van Helden","year":"2006","unstructured":"van Helden S et al (2006) Risk of new clinical fractures within 2 years following a fracture. Osteoporos Int 17(3):348\u2013354","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06845-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06845-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06845-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T08:02:52Z","timestamp":1695196972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06845-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6845"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06845-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"12 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ta-Wei Tai: honoraria for lectures and attending meetings from Amgen and Alvogen\/Lotus. Jawl-Shan Hwang: honoraria for lectures, attending meetings, and\/or travel from Eli Lilly, Roche, Amgen, Merck, Alvogen\/Lotus. Chih-Hsing Wu: honoraria for lectures, attending meetings, and\/or travel from Eli Lilly, Roche, Amgen, Merck, Servier laboratories, GE Lunar, Harvester, TCM Biotch, Alvogen\/Lotus. Jawl-Shan Hwang: honoraria for lectures and attending meetings from Amgen and Alvogen\/Lotus. Yi-Lun Tsai, Chia-Chun Li, Chien-An Shih and Yin-Fan Chang declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}